Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to ...(nce of weight gain of 7 percentor more f...),Health

Date:9/2/2008

nce of weight gain of 7 percent or more from baseline was significantly higher for patients treated with oral olanzapine (21.4 percent), olanzapine LAI 150 mg every two weeks (16.4 percent), olanzapine LAI 300 mg every two weeks (20.7 percent) and olanzapine LAI 405 mg every four weeks (15.2 percent) when compared with patients treated with olanzapine LAI 45 mg every 4 weeks (8.3 percent, all p less than or equal to .05). The incidence of all injection site reactions, including injection pain, was 2.8 percent. Adverse events reported in 5 percent or more of patients were insomnia, weight increase, anxiety, nasopharyngitis, somnolence and headache. In HGKA, two patients experienced and recovered fully from Olanzapine LAI Post-Injection Syndrome, which includes a range of symptoms of sedation (ranging from mild in severity to unconsciousness) and/or delirium (including confusion, disorientation, agitation, anxiety and other cognitive impairment). Other symptoms include extrapyramidal symptoms, dysarthria, ataxia, aggression, dizziness, weakness, hypertension and convulsion.

Earlier this year, data pertaining to the study's primary relapse endpoint was disclosed at the Schizophrenia International Research Society (SIRS) Conference. These data showed that patients treated with all three higher doses of olanzapine LAI had longer time to symptom exacerbation than patients who received the reference dose and that the four-week 405 mg and the pooled two-week dosing regimens showed non inferiority when compared to oral olanzapine and to each other.

About Olanzapine LAI Post-Injection Syndrome Analysis

As with all medications, there are risks associated with the use of long- acting injections. Across all olanzapine LAI clinical trials, olanzapine LAI showed a similar safety profile as the oral formulation except for injection- related events, including Olanzapine LAI Post-Injection Syndrome.

The purpose of this analysis was to review the Olanzapine
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
5. New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
8. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma